NASDAQ: SERASera Prognostics Inc Stock
$7.00+0.61 (+9.55%)
Updated Oct 11, 2024
SERA Price
$7.00
Fair Value Price
-$1.39
Market Cap
$233.58M
52 Week Low
$1.56
52 Week High
$12.36
P/E
-7.14x
P/B
3.91x
P/S
1,822.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$107.00k
Earnings
-$31.54M
Gross Margin
1.9%
Operating Margin
-29,432.71%
Profit Margin
-29,472%
Debt to Equity
0.42
Operating Cash Flow
-$15M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SERA Overview
Sera Prognostics Incorporated is a women's health diagnostic company. It offers biomarker tests for improving pregnancy outcomes by testing for preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. PreTRM, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, was one of the company's first successes. Sera Prognostics was incorporated in 2008 and is headquartered in Salt Lake City, UT.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SERA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SERA ($7.00) is overvalued by 602.9% relative to our estimate of its Fair Value price of -$1.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SERA ($7.00) is not significantly undervalued (602.9%) relative to our estimate of its Fair Value price of -$1.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SERA due diligence checks available for Premium users.
Be the first to know about important SERA news, forecast changes, insider trades & much more!
SERA News
Valuation
SERA fair value
Fair Value of SERA stock based on Discounted Cash Flow (DCF)
Price
$7.00
Fair Value
-$1.39
Undervalued by
602.90%
SERA ($7.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SERA ($7.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SERA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.14x
Industry
37.42x
Market
27.31x
SERA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.91x
Industry
4.54x
SERA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SERA's financial health
Profit margin
Revenue
$24.0k
Net Income
-$8.3M
Profit Margin
-34,595.8%
SERA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SERA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$84.9M
Liabilities
$25.1M
Debt to equity
0.42
SERA's short-term assets ($51.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SERA's short-term assets ($51.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SERA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
$5.1M
Financing
$1.2M
SERA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SERA vs Diagnostic & Research Stocks
Sera Prognostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.